PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
PTC Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was 12.8%. For fiscal 2025 it was 50.1%, against -37.5% the year before. The highest annual figure on record is 50.1% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.1% | +87.6 |
| FY2024 | Dec 31, 2024 | -37.5% | +9.4 |
| FY2023 | Dec 31, 2023 | -46.9% | +17.2 |
| FY2022 | Dec 31, 2022 | -64.0% | +5.5 |
| FY2021 | Dec 31, 2021 | -69.5% | +43.9 |
| FY2020 | Dec 31, 2020 | -113.4% | −34.8 |
| FY2019 | Dec 31, 2019 | -78.6% | −34.9 |
| FY2018 | Dec 31, 2018 | -43.7% | −10.6 |
| FY2017 | Dec 31, 2017 | -33.1% | +126.6 |
| FY2016 | Dec 31, 2016 | -159.7% | +294.9 |
| FY2015 | Dec 31, 2015 | -454.6% | −60.8 |
| FY2014 | Dec 31, 2014 | -393.8% | −262.9 |
| FY2013 | Dec 31, 2013 | -130.8% | −51.9 |
| FY2012 | Dec 31, 2012 | -79.0% | −108.0 |
| FY2011 | Dec 31, 2011 | 29.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 7.0% | +5.6 |
| Q2 FY2026 | Jun 30, 2026 | 41.3% | +60.9 |
| Q1 FY2026 | Mar 31, 2026 | 16.5% | −66.0 |
| Q4 FY2025 | Dec 31, 2025 | -43.3% | +32.9 |
| Q3 FY2025 | Sep 30, 2025 | 1.4% | +29.1 |
| Q2 FY2025 | Jun 30, 2025 | -19.5% | +2.0 |
| Q1 FY2025 | Mar 31, 2025 | 82.5% | +104.1 |
| Q4 FY2024 | Dec 31, 2024 | -76.2% | −78.1 |
| Q3 FY2024 | Sep 30, 2024 | -27.7% | +32.4 |
| Q2 FY2024 | Jun 30, 2024 | -21.5% | +76.5 |
| Q1 FY2024 | Mar 31, 2024 | -21.6% | +31.7 |
| Q4 FY2023 | Dec 31, 2023 | 1.9% | +121.6 |
| Q3 FY2023 | Sep 30, 2023 | -60.1% | −28.7 |
| Q2 FY2023 | Jun 30, 2023 | -98.0% | −42.2 |
| Q1 FY2023 | Mar 31, 2023 | -53.4% | +4.8 |
| Q4 FY2022 | Dec 31, 2022 | -119.7% | −68.4 |
| Q3 FY2022 | Sep 30, 2022 | -31.4% | +35.7 |
| Q2 FY2022 | Jun 30, 2022 | -55.8% | +28.6 |
| Q1 FY2022 | Mar 31, 2022 | -58.2% | +25.0 |
| Q4 FY2021 | Dec 31, 2021 | -51.3% | +29.8 |
| Q3 FY2021 | Sep 30, 2021 | -67.1% | −20.5 |
| Q2 FY2021 | Jun 30, 2021 | -84.4% | +164.5 |
| Q1 FY2021 | Mar 31, 2021 | -83.2% | +53.0 |
| Q4 FY2020 | Dec 31, 2020 | -81.1% | −5.6 |
| Q3 FY2020 | Sep 30, 2020 | -46.6% | +38.1 |
| Q2 FY2020 | Jun 30, 2020 | -248.9% | −203.6 |
| Q1 FY2020 | Mar 31, 2020 | -136.2% | −7.2 |
| Q4 FY2019 | Dec 31, 2019 | -75.5% | −22.9 |
| Q3 FY2019 | Sep 30, 2019 | -84.7% | +5.3 |
| Q2 FY2019 | Jun 30, 2019 | -45.3% | −37.2 |
| Q1 FY2019 | Mar 31, 2019 | -129.0% | −99.2 |
| Q4 FY2018 | Dec 31, 2018 | -52.6% | −62.0 |
| Q3 FY2018 | Sep 30, 2018 | -90.0% | −16.1 |
| Q2 FY2018 | Jun 30, 2018 | -8.1% | +18.0 |
| Q1 FY2018 | Mar 31, 2018 | -29.9% | +69.8 |
| Q4 FY2017 | Dec 31, 2017 | 9.4% | +108.9 |
| Q3 FY2017 | Sep 30, 2017 | -73.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -26.1% | – |
| Q1 FY2017 | Mar 31, 2017 | -99.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -99.5% | – |
See a number that looks wrong?